Research Article

Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy

Volume: 52 January 26, 2026
TR EN

Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy

Abstract

The purpose of this study was to assess dermatological lesions in hematologic malignancy patients. Patient file records pertaining to patients diagnosed with hematologic malignancies and followed up in our center between 2019 and 2024 will be retrospectively examined for demographic information, hematologic disease diagnoses, clinical features, dermatological examination data obtained with dermatology consultation, pathology results of biopsies taken from skin lesions, and the presence of other malignancies. The study comprised 241 participants with hematologic malignancies. The male to female ratio was 1.3, and the median age was 64. Acute myeloid leukemia (AML) accounted for 24.1% of diagnoses, while multiple myeloma (MM) came in second with 18.3%. With a rate of 14.9%, dermatitis was the most frequent form of lesion, followed by drug response (14.5%). In the AML group, dermatitis and fungal infection were the most frequent lesions, while in the MM group, medication reactions were more common. Patients with malignancy experienced urticaria considerably more frequently (p=0.004). At the time of lesion development, 81.7% of the patients were receiving chemotherapy, with alkylating drugs being the most frequently utilized agents (24.9%). Twenty percent of individuals who had biopsies reported having vasculitis and drug-related dermatological responses. 98.8% of the patients received local/topical supportive treatments without stopping systemic treatment. According to this study, dermatological lesions in hematologic malignancies may be connected to the course of the disease as well as treatment. These results imply that routine follow-up for hematologic patients should include a dermatological evaluation.

Keywords

References

  1. 1. Cerroni L, Zenahlik P, Höfler G, Kaddu S, Smolle J, Kerl H. Cutaneous involvement in leukemia. Am J Dermatopathol. 2002;24(5):287-294. doi:10.1097/00000372-200210000-00001
  2. 2. Vassileva S, Mateev G, Parish JL. Leukemia cutis. Clin Dermatol. 2000;18(3):319-325. doi:10.1016/S0738-081X(00)00128-0
  3. 3. Robak E, Braun M, Robak T. Leukemia cutis—the current view on pathogenesis, diagnosis, and treatment. Cancers (Basel). 2023;15(22):5393. doi:10.3390/cancers15225393
  4. 4. Robak T, Jamroziak K, Smolewski P, et al. Extramedullary and extranodal manifestations in chronic lymphocytic leukemia–an update. Ann Hematol. 2024;103(9):3369-3383. doi:10.1007/s00277-024-05817-4
  5. 5. Elder DE, Elenitsas R, Johnson BL, Murphy GF. Lever's Histopathology of the Skin. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
  6. 6. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2
  7. 7. Cowen EW, Nguyen JC. Cutaneous manifestations of hematologic diseases. Hematology Am Soc Hematol Educ Program. 2017;2017(1):57-63. doi:10.1182/asheducation-2017.1.57
  8. 8. Zhang Y, Li T, Huang Y. Cutaneous manifestations in patients with hematologic malignancies: a retrospective cohort study. J Dermatol Sci. 2020;98(3):211-217. doi:10.1016/j.jdermsci.2020.04.007

Details

Primary Language

English

Subjects

Haematology

Journal Section

Research Article

Publication Date

January 26, 2026

Submission Date

September 16, 2025

Acceptance Date

December 18, 2025

Published in Issue

Year 2026 Volume: 52

APA
Albayrak, E., Vural, E., Bilen, Y., Gürsoy, V., & Sadri, S. (2026). Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy. Journal of Uludağ University Medical Faculty, 52, 1782776. https://doi.org/10.32708/uutfd.1782776
AMA
1.Albayrak E, Vural E, Bilen Y, Gürsoy V, Sadri S. Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy. Journal of Uludağ University Medical Faculty. 2026;52:1782776. doi:10.32708/uutfd.1782776
Chicago
Albayrak, Emre, Ece Vural, Yusuf Bilen, Vildan Gürsoy, and Sevil Sadri. 2026. “Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy”. Journal of Uludağ University Medical Faculty 52 (January): 1782776. https://doi.org/10.32708/uutfd.1782776.
EndNote
Albayrak E, Vural E, Bilen Y, Gürsoy V, Sadri S (January 1, 2026) Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy. Journal of Uludağ University Medical Faculty 52 1782776.
IEEE
[1]E. Albayrak, E. Vural, Y. Bilen, V. Gürsoy, and S. Sadri, “Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy”, Journal of Uludağ University Medical Faculty, vol. 52, p. 1782776, Jan. 2026, doi: 10.32708/uutfd.1782776.
ISNAD
Albayrak, Emre - Vural, Ece - Bilen, Yusuf - Gürsoy, Vildan - Sadri, Sevil. “Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy”. Journal of Uludağ University Medical Faculty 52 (January 1, 2026): 1782776. https://doi.org/10.32708/uutfd.1782776.
JAMA
1.Albayrak E, Vural E, Bilen Y, Gürsoy V, Sadri S. Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy. Journal of Uludağ University Medical Faculty. 2026;52:1782776.
MLA
Albayrak, Emre, et al. “Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy”. Journal of Uludağ University Medical Faculty, vol. 52, Jan. 2026, p. 1782776, doi:10.32708/uutfd.1782776.
Vancouver
1.Emre Albayrak, Ece Vural, Yusuf Bilen, Vildan Gürsoy, Sevil Sadri. Evaluation of Dermatological Lesions in Patients With Hematologic Malignancy. Journal of Uludağ University Medical Faculty. 2026 Jan. 1;52:1782776. doi:10.32708/uutfd.1782776

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023